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Serum chemokine profiles in patients 
with alopecia areata
The role of chemokines was studied in patients with alopecia 
areata (AA) and correlated with disease activity. Serum samples 
from 85 patients with AA, 20 patients with atopic dermatitis, 
20 patients with psoriasis vulgaris and 28 normal controls were 
examined by the cytometric bead array assay assessing MIG, 
RANTES, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β and eotaxin levels. 
Secreted chemokine levels from peripheral blood mononuclear 
cells (PBMC) of patients with AA were also investigated. Serum 
MIG, RANTES, IL-8 and eotaxin levels were selectively increased 
in patients with AA compared with normal controls. Levels of 
MIG, RANTES and IL-8 secreted from PBMC of patients with AA 
were also increased. Elevated serum MIG and RANTES levels 
significantly correlated with the disease activity. RANTES lev-
els were not associated with a predisposition to atopy. MIG and 
RANTES may play an important role in the development of AA 
and may prove to be useful as markers of the disease activity and 
as therapeutic targets. Br J Dermatol 2007; 157:466–73
Mite-related bacterial antigens 
stimulate inflammatory cells in rosacea
The role of Demodex folliculorum mites in the pathogenesis of rosa-
cea is controversial. Selective antibiotics are effective in reducing the 
inflammatory changes of papulopustular rosacea, but their mode of 
action is unknown. Lacey et al. investigated whether a D. folliculo-
rum-related bacterium was capable of expressing antigens that could 
stimulate an inflammatory immune response in patients with rosa-
cea. A bacterium (Bacillus oleronius) was isolated from a D. follicu-
lorum mite extracted from the face of a patient with papulopustular 
rosacea. This bacterium produced antigen(s) capable of preferential-
ly stimulating peripheral blood mononuclear cells proliferation in 16 
of 22 (73%) patients with rosacea but only five of 17 (29%) control 
subjects (P = 0.0105). They were able to demonstrate immunoreac-
tivity in sera of patients with rosacea to two proteins of size 62 and 
83 kDa. No immunoreactivity to these proteins was recorded when 
probing with sera from control patients. Antigenic proteins related to 
a bacterium (B. oleronius), isolated from a D. folliculorum mite, have 
the potential to stimulate an inflammatory response in patients with 
rosacea. Br J Dermatol 2007; 157: 474–81
Topical treatment of nail diseases
Topical treatment of nail diseases is hampered by the nail plate barri-
er, which prevents penetration of antifungal agents. Finnen and col-
leagues have studied whether acidified nitrite can penetrate the nail 
barrier and cure onychomycosis in 13 patients with culture-positive 
onychomycosis, and have determined whether nitrosospecies can 
bind to the nail plate. Nails were treated with a mixture of sodium 
nitrite and citric acid at two different doses. Immunohistochemistry, 
ultraviolet-visible absorbance spectroscopy and serial chemical 
reduction of nitrosospecies followed by chemiluminescent detec-
tion of NO were used to measure nitrosospecies. Acidified nitrite-
treated nails and the nitrosothiols S-nitrosopenicillamine (SNAP) 
and S-nitrosoglutathione (GSNO) were added to Trichophyton 
rubrum and T. mentagrophytes cultures in liquid Saboraud medium 
and growth measured. S-nitrosothiols were formed in the nail fol-
lowing a single treatment of low- or high-dose sodium nitrite and 
citric acid. Repeated exposure to high-dose acidified nitrite led to 
additional formation of N-nitrosamines. S-nitrosothiol formation 
caused the nail to become antifungal to T. rubrum and T. mentagro-
phytes. Antifungal activity was Cu2+ sensitive. The NO donor nitro-
sothiols SNAP and GSNO were also found to be antifungal. Topical 
acidified nitrite treatment of patients with onychomycosis resulted 
in > 90% becoming culture negative for T. rubrum. Acidified nitrite 
exploits the nature of the nail barrier and utilizes it as a means of 
delivery of NO/nitrosothiol-mediated antifungal activity. Thus the 
principal obstacle to therapy in the nail becomes an effective deliv-
ery mechanism. Br J Dermatol 2007; 157: 494–500
No association between tetracycline 
class antibiotics used for acne vulgaris 
and lupus erythematosus
The association between minocycline use for the treatment of acne 
and drug-induced lupus erythematosus (LE) is well known. Margolis 
et al. have looked to see if this is true of other tetracyclines used 
in treating acne. They studied a retrospective cohort of individu-
als aged 15–35 years with acne within the practices of the gener-
al practice physicians in the U.K. who participated in The Health 
Information Network: 97,694 subjects with acne were followed for 
520 000 person-years. They were on average about 22 years old and 
57.5% were female. Minocycline exposure was noted in 24.8% of 
subjects, doxycycline exposure in 15.6%, other tetracyclines in 
42.3%, and 17.3% had not received a tetracycline antibiotic. The 
overall hazard ratio for the association of minocycline to LE was 
2.64 (95% confidence interval 1.51–4.66) and when adjusted for 
age and gender was 3.11 (1.77–5.48). Those affected were often 
treated for LE. No association was noted for doxycycline and the 
other tetracyclines. Br J Dermatol 2007; 157: 540–6
Chronic hepatitis B reactivation and 
systemic corticosteroid therapy
Treating patients with immunobullous diseases with high-dose cor-
ticosteroids can be very hazardous. Reactivation of chronic hepa-
titis B virus (HBV) infection should be added to the list of potential 
fatal complications. Yang et al. report four HBV carriers with viral 
hepatitis flare who were identified from a retrospectively identified 
cohort of 98 patients receiving at least 6 months of systemic corti-
costeroids. Two patients suffered fulminant hepatitis and died, while 
the remaining two patients experienced recurrent hepatitis flare fol-
lowing antiviral medication. The mean time from the start of cor-
ticosteroids to the time of HBV reactivation was 10.5 months. The 
authors recommend screening for serum hepatitis B markers before 
systemic corticosteroid therapy is initiated Br J Dermatol 2007; 157: 
587–90
